Capture SBIR Gene Therapy Audience via FOIA-Driven Lead Generation
- Organization
- National Science Foundation (SBIR Program)
- Sector
- SBIR-funded gene therapy researchers
- Location
- United States
Source reference
Executive summary
Current state
NSF awarded $305,000 SBIR Phase I funding to AICONIC BIOSCIENCES for developing gene therapy to overcome AAV cargo size limitations, creating a structural commercial gap where cash-rich but bandwidth-poor biotechs must spend non-dilutive capital quickly while navigating complex technical and regulatory challenges.
Market catalyst
NSF publishes detailed data on SBIR awards but doesn't aggregate or segment it for specific technical niches. Researchers working on identical problems (AAV cargo limitations) have no way to find each other or share resources, creating an isolated community that can be aggregated.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.
Field notes
Intelligence ledger
Add new evidence, corrections, or practical context to this directive. Keep claims attributable to a source where possible.
Sign in to add intelligence or vote on a field note.
Field intel logs: [ 0 ] entries. No operative updates submitted for this directive. Submit intel to claim clearance.